[1]Torre LA, Bray F, Siegel RL, Ferlay J, Lort-Tetieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
[2]Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, Ishiguro T, et al. Prognostic significance of circumferential cell surface immunoreactivity of glypican–3 in hepatocellular carcinoma. Liver Int. 2011;31:120–31.
[3]Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, et al. High pre-operative levels of serum glypican–3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.Int J Cancer. 2015;137:1643–51.
[4]Ohno A, Yorita K, Haruyama Y, Kondo K, Kato A, Ohtomo T, et al. Aberrant expression of monocarboxylate transporter 4 in tumor cells predicts an unfavourable outcome in patients with hepatocellular carcinoma.Liver Int. 2014;34:942–52.
[5]Filmus J, Song H, Shi W, Duenas Gonzalez A, Kaya M, Cano-Gauci D. Glypican–3 is a novel inhibitor of insulin-like growth factor signaling. Medicina (B Aires).1999;59:546.
[6]Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican–3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245–54.
[7]Zhang J, Zhang M, Ma H, Song X, He L, Ye X, et al. Overexpression of glypican–3 is a predictor of poor prognosis in hepatocellular carcinoma: an updated meta-analysis. Medicine (Baltimore). 2018;97:e11130.
[8]Liu H, Yang C, Lu W, Zeng Y. Prognostic significance of glypican–3 expression in hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2018;97:e9702.
[9]Bovenzi CD, Hamilton J, Tassone P, Johnson J, Cognetti DM, Luginbuhl A, et al. Prognostic indications of elevated MCT4 and CD147 across cancer types: a meta-analysis. Biomed Res Int. 2015;2015:242437.
[10]Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr. 2012;44:127–39.
[11]Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF–1alpha-dependent mechanism. J Biol Chem. 2006;281:9030–7.
[12]Xiong XX, Qiu XY, Hu DX, Chen XQ. Advances in hypoxia-mediated mechanisms in hepatocellular carcinoma. Mol Pharmacol. 2017;92:246–55.
[13]Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000;19:3896–904.
[14]Kataoka H, DeCastro R, Zucker S, Biswas C. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res. 1993;53:3154–8.
[15]Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434–9.
[16]Gao HJ, Zhao MC, Zhang YJ, Zhou DS, Xu L, Li GB, et al. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. J Cancer Res Clin Oncol. 2015;141:1151–62.
[17]Chen HL, OuYang HY, Le Y, Jiang P, Tang H, Yu ZS, et al. Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy. Cancer Med. 2018;7:5339–50.
[18]Takai H, Kato A, Ishiguro T, Kinoshita Y, Karasawa Y, Otani Y, et al. Optimization of tissue processing for immunohistochemistry for the detection of human glypican–3. Acta Histochem. 2010;112:240–50.
[19]Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008;68:9832–8.
[20]Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2009;378:279–84.
[21]Xiang YY, Ladeda V, Filmus J. Glypican–3 expression is silenced in human breast cancer. Oncogene. 2001;20:7408–12.
[22]Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene. 2000;19:410–6.
[23]Thienpont B, Steinbacher J, Zhao H, D’Anna F, Kuchnio A, Ploumakis A, et al. Tumor hypoxia causes DNA hypermethylation by reducing TET activity. Nature. 2016;537:63–8.
[24]Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology. 2007;46:1541–7.
[25]Luan F, Liu P, Ma H, Yue X, Liu J, Gao L, et al. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma. Int J Biochem Cell Biol. 2014;55:129–35.
[26]Taguchi A, Emoto M, Okuya S, Fukuda N, Nakamori Y, Miyazaki M, et al. Identification of Glypican3 as a novel GLUT4-binding protein. Biochem Biophys Res Commun. 2008;369:1204–8.